Pharmafile Logo
Pharmafocus logo
Advanced Search
lilly_corporate_hq

Lilly announces plan to expand global access to health care

October 19, 2016
Research and Development Eli Lilly, Lilly 30x30, global health

Eli Lilly has announced a project, known as Lilly 30×30, which is a five-year, $90 million investment to improve access …

News

Roche’s immunotherapy cancer drug given FDA approval

October 19, 2016
Research and Development Cancer, FDA, Genentech, Roche, immunotherapy, lung cancer

Coming off the back of earlier positive news this month, Roche has revealed that their drug, Tecentriq, has been given …

News

Recipharm to open largest Nordic GLP bioanalysis lab

October 19, 2016
Manufacturing and Production, Research and Development Recipharm, Sweden, expansion

Contract development and manufacturing firm Recipharm has announced plans to invest five million Swedish Krona (SEK) in a new GLP-compliant …

News
fdaoutsideweb

FDA grants $23 million to boost research on rare diseases

October 19, 2016
Research and Development Cancer, FDA, clinical trials, oncology

The FDA has continued their push to provide funding for experimental clinical trials into treatments of rare diseases. The FDA, …

News
shutterstock_138095450

Quark to set up “largest biotechnology fund in Canada” for $500m

October 18, 2016
Manufacturing and Production, Research and Development Canada, Quark Venture, Vancouver, fund

Canadian venture capital firm Quark Venture is to partner up with China’s GF Securities to launch a “largest of its …

News
pillsphotos1

Research suggests that anti-inflammatory drugs may offer alternative to anti-depressants

October 18, 2016
Manufacturing and Production University of Cambridge, anti-cytokine, anti-inflammatory, depression

Researchers at the University of Cambridge analysed data from 20 clinical trials involving anti-cytokine drugs, which are commonly used to …

News
c_agsandrew_-_fotolia

IBM and Quest forge precision cancer treatment partnership

October 18, 2016
Manufacturing and Production, Medical Communications Cancer, Precision Medicine, Quest, ibm, oncology

IBM has revealed it is to join forces with clinical laboratory service provider Quest Diagnostics in a bid to utilise …

News
pfizer_sky

Pfizer sets release date for rival to J&J’s blockbuster drug

October 18, 2016
Manufacturing and Production J&J, JJ, Johnson & Johnson, Pfizer, Remicade, inflectra

Pfizer have announced that they will begin shipping their rival to Johnson & Johnson’s Remicade by the end of November. …

News
ipos0_l

Regeneron and Teva’s experimental drug halted by FDA clinical hold

October 17, 2016
Manufacturing and Production Regeneron, Teva, back pain, osteoarthritis

Regeneron Pharmaceuticals and Teva Pharmaceuticals had only just agreed a deal worth a potential $2.6 billion to co-develop Regeneron’s fasinumab …

News

Wickham Laboratories Announces Renewal of FDA Accreditation

October 17, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Wickham Laboratories announces that the United States Food and Drug Administration (FDA) inspection conducted 15th-17th of February 2016 has now …

News
Press release
shutterstock_38078521

Apitope reclaims multiple sclerosis treatment from Merck after 7 years

October 17, 2016
Sales and Marketing ATX-MS-1467, Apitope, Merck, multiple sclerosis

Apitope has announced it has reclaimed the global rights to its multiple sclerosis (MS) treatment ATX-MS-1467 from Merck for the …

News
valeant_logo

Valeant Pharmaceutical release their latest price increases

October 17, 2016
Sales and Marketing

Valeant Pharmaceutical announced, on 14 October, that their Patient Access and Pricing Committee had decided on a price range increase …

News
hanmi

Hanmi Pharmaceutical raided over insider trading suspicions

October 17, 2016
Sales and Marketing Boehringer Ingelheim, Genentech, Hanmi Pharmaceutical, south korea

At the end of September, we reported on a busy 24-hour for Hanmi Pharmaceutical, as they secured a deal with …

News
ema_building_face_web

EMA grants conditional approval for biliary cholangitis treatment

October 17, 2016
Sales and Marketing EMA, intercept, ocaliva, primary biliary cholangitis

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has voiced its approval of Intercept’s Ocaliva …

News
celgene_1_02

Celgene trial displays promising results for Crohn’s disease alternative treatment

October 17, 2016
Sales and Marketing Celgene, Celgene corporation, Crohn’s disease, clinical trials, crohn's disease, phase I, trial

Celgene International, part of Celgene Corporation, has released the results from a Phase Ib trial showing improvement in patients suffering …

News
chris_nowers

Kite Pharma appoints Chris Nowers as Head of Europe

October 14, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Chris Nowers, London, kite pharma

Kite Pharma announced on 13 October that it had appointed Chris Nowers as its Head of Europe. Nowers will be …

Appointment
top_ten_1

Top Ten articles in the pharma industry this week

October 14, 2016
Medical Communications news, october, pharmaceutical, top 10, top ten, top ten stories

This week has seen a lot of news regarding specific drugs going through trial and some impressive results within. Read …

News
regeneron

Regeneron and Ocular Therapeutix to collaborate in potential $315 million deal

October 14, 2016
Medical Communications Bayer, Eyelea, Ocular Therapeutix, Regeneron Pharmaceuticals, wet AMD

Regeneron Pharmaceuticals and Ocular Therapeutix have entered into a deal that will see them collaborate to develop a sustained release …

News

NICE plans new “fast-track” appraisal option

October 14, 2016
Medical Communications, Sales and Marketing NHS, NICE

The National Institute for Health and Care Excellence (NICE) has proposed the introduction of a fast-track process which could make …

News
janssen_latest_logo_on_sign

NICE knocks back Janssen rare disease drug

October 13, 2016
Medical Communications Janssen, NICE, imbruvica

NICE has announced its rejection of Janssen’s Imbruvica (ibrutinib) for the treatment of specific cases of Waldenstrom’s macroglobulinaemia (WM) – …

News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026